MAPT and Mental deterioration: To advance our understanding of the disparate findings among neurodegenerative biomarkers and to establish a foundation for clinical application, it is essential to examine the associations between these biomarkers and amyloid–tau pathology, as well as their correlation with cognitive decline throughout the progression of the disease.